drugset
drugset / Trial / NCT04223349

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349 ↗

Phase 1 Completed 66 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and food on the PK of single-dose of JNJ-70033093 in healthy participants.

Timeline

Start
2020-01-10
Primary completion
2020-04-08
Completion
2020-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Milvexian Small molecule — Oral

Indications

No indication recorded.